Late effects of anticancer chemotherapy: It ’s hard to trust your body, after it’s betrayed you
Lily was diagnosed at 14 years old with stage four Hodgkin's lymphoma and received six rounds of chemotherapy and two weeks of radiotherapy. She survived but now lives with the long term effects of that therapy - and joins us to discuss how it has impacted her quality of life.
We're also joined by Saif Ahmad and Thankamma Ajithkumar, oncologists from Cambridge University Hospitals NHS Foundation Trust, who give advice for generalists on late effects of anticancer chemotherapy that may affect quality of life.
Read the full clinical review:
http://www.bmj.com/content/354/bmj.i4567 (Source: The BMJ Podcast)
Source: The BMJ Podcast - September 8, 2016 Category: General Medicine Authors: BMJ Group Source Type: podcasts
Multidisciplinary team approach to side effects management
Jervoise Andreyev, MA, PhD, FRCP of The Royal Marsden NHS Foundation Trust, London, United Kingdom discusses the need for a multidisciplinary team approach to cancer care. Specialists from various fie...
Author: VJOncology
Added: 08/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - August 26, 2016 Category: Cancer & Oncology Source Type: podcasts
ASCO 2016 Melanoma Highlights: developments in immunotherapy, MEK inhibitors, and follow-up data on checkpoint inhibitors
James Larkin, MD, PhD, of the Royal Marsden NHS Foundation Trust, London, UK, discusses the highlights in melanoma from the 2016 Annual Meeting of the American Society of Oncology (ASCO), held in Chic...
Author: VJOncology
Added: 08/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - August 26, 2016 Category: Cancer & Oncology Source Type: podcasts
The on-going search for clinical trials suitable for patients with aggressive melanoma
James Larkin, MD, PhD, of the Royal Marsden NHS Foundation Trust, London, UK, discusses aggressive melanoma, which he considers to be one of the key areas in the field. <br />One of the problems that pati...
Author: VJOncology
Added: 08/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - August 26, 2016 Category: Cancer & Oncology Source Type: podcasts
Availability of clinical trials for patients with brain metastases and more aggressive diseases
James Larkin, MD, PhD, of the Royal Marsden NHS Foundation Trust, London, UK, discusses the session Clinical problems in oncology that he was involved in at the 2016 Annual Meeting of the American S...
Author: VJOncology
Added: 08/26/2016 (Source: Oncology Tube)
Source: Oncology Tube - August 26, 2016 Category: Cancer & Oncology Source Type: podcasts
Treatment options for stage III melanoma patients
James Larkin, MD, PhD, of the Royal Marsden NHS Foundation Trust, London, UK, explains the treatment options available for patients with stage III melanoma, which means that the disease has been cured...
Author: VJOncology
Added: 08/25/2016 (Source: Oncology Tube)
Source: Oncology Tube - August 25, 2016 Category: Cancer & Oncology Source Type: podcasts
The importance of patient involvement in discussing treatment options
James Larkin, MD, PhD, of the Royal Marsden NHS Foundation Trust, London, UK, discusses the upcoming Melanoma Patient Conference in June 2016. He believes that it is a very positive event, and patient...
Author: VJOncology
Added: 08/25/2016 (Source: Oncology Tube)
Source: Oncology Tube - August 25, 2016 Category: Cancer & Oncology Source Type: podcasts
Advancements in use of combination drugs in clinical trials: nivolumab, pembrolizumab, and more
James Larkin, MD, PhD, of the Royal Marsden NHS Foundation Trust, London, UK, discusses the next steps for the treatment of advanced melanoma. Dr Larkin first discusses that it really comes back down ...
Author: VJOncology
Added: 08/18/2016 (Source: Oncology Tube)
Source: Oncology Tube - August 18, 2016 Category: Cancer & Oncology Source Type: podcasts
Influence of new immunotherapy checkpoint inhibitors in melanoma
James Larkin, MD, PhD, of the Royal Marsden NHS Foundation Trust, London, UK discusses the use of the new immunotherapy checkpoint inhibitors, and the influence they have had on melanoma. <br />He proceed...
Author: VJOncology
Added: 08/17/2016 (Source: Oncology Tube)
Source: Oncology Tube - August 17, 2016 Category: Cancer & Oncology Source Type: podcasts
Poor adherence to antihypertensives
It is estimated that 50% of patients who have what appears to be treatment resistant hypertension are actually not taking their drugs as prescribed.
Indranil Dasgupta, a consultant nephrologist at the Heart of England NHS Foundation Trust joins us to discuss what factors may influence non-adherence, and how to encourage patients to divulge that... (Source: The BMJ Podcast)
Source: The BMJ Podcast - August 16, 2016 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
Poor adherence to antihypertensives
It is estimated that 50% of patients who have what appears to be treatment resistant hypertension are actually not taking their drugs as prescribed.
Indranil Dasgupta, a consultant nephrologist at the Heart of England NHS Foundation Trust joins us to discuss what factors may influence non-adherence, and how to encourage patients to divulge that information.
Read the full article:
http://www.bmj.com/content/354/bmj.i3268 (Source: The BMJ Podcast)
Source: The BMJ Podcast - August 16, 2016 Category: General Medicine Authors: BMJ Group Source Type: podcasts
The future of multiple myeloma treatment: genetic tests and frailty
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD fromOxford University Hospitals NHS Foundation Trust, Oxford, UK discusses the different forms of multiple myeloma (MM) and approaches to determine better t...
Author: VJHemOnc
Added: 07/21/2016 (Source: Oncology Tube)
Source: Oncology Tube - July 21, 2016 Category: Cancer & Oncology Source Type: podcasts
Dexmedetomidine: its use in intensive care medicine and anaesthesia
Dr Joe Sebastian, consultant neuroanaesthetist from Salford Royal Hospital NHS Foundation Trust and Dr Victoria Scott-Warren, specialty trainee from the North Western Deanery, discusses their article "Dexmedetomidine: its use in intensive care medicine and anaesthesia", published in the July 2016 edition of BJA Education. Topics discussed include recent evidence on dexmedetomidine, its pharmacological mechanism, and clinical tips for its use. (Source: CEACCP Podcasts)
Source: CEACCP Podcasts - July 6, 2016 Category: Anesthesiology Authors: Oxford University Press Source Type: podcasts
